API | monalizumab

monalizumab Report issue

Biologics mAb Experimental

AACT DrugBank

Active Ingredient History

NOW

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
monalizumab

More Chemistry

Pharmacology

Mechanism of Action:
- NKG2-A/NKG2-B type II integral membrane protein (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

iph2201 | monalizumab

Organizations (22)

Research & Development (22)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (17)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (17)

Arthritis, Rheumatoid (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 2)

COVID-19 (Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Genital Neoplasms, Female (Phase 1)

Head and Neck Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 1)

Inflammation (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Microsatellite Instability (Phase 2)

Neoplasms (Phase 2)

Sepsis (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 20
# of Trial Organizations: 22

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue